Viral Genetics, Inc. develops protein based therapeutic and diagnostic products for the treatment of infectious disease, autoimmune conditions, and immunological deficiency.
read more
| Detailed Quote for Viral Genetics Inc. (VRAL) |
|
|
|
|
Viral Genetics, Inc. (PINK:VRAL), a development-stage biotechnology company, is promoted again. Additionally, the company posted a President's Letter to Shareholders.read more
Three emails, two promoters, $30 thousand compensation. In a nutshell, this is what has determined the market performance of Viral Genetics, Inc. (PINK:VRAL) for the last two days.read more
Last Monday, i.e on Nov. 21, third parties invested a total of $22,500 into a paid advertising campaign in favor of Viral Genetics, Inc. (PINK:VRAL). As a result, VRAL stock gained 9.6% on Monday and 31.25% on Tuesday, and that was pretty much the end of it.read more
Until a couple of days ago, Viral Genetics, Inc. (PINK:VRAL) was one of the few penny stocks that had never been subject to paid advertising. Not anymore. The first couple of promotions in support of VRAL stock reached our database last weekend.read more
Minimal price movement, moderate volume surge. Although this combination is seldom associated with pink sheets, Viral Genetics, Inc. (PINK:VRAL) has recently been developing a very similar performance on the stock market. Completely devoid of promotional support, VRAL stock somehow manages to hold relatively good market positions.read more
My new Biotech Blastoff Alert is VRAL - Viral Genetics
About VRAL Viral Genetics, Inc., a biotechnology company, discovers and develops immune-based therapies for the treatment of HIV/AIDS and other infectious, autoimmune, and immunological deficiency disorders. It develops its products using its thymus nuclear protein compound. The company’s product includes VGV-X for the treatment of HIV infection and AIDS. It also develops VGV-L for Lyme read more
My new Biotech Blastoff Alert is VRAL - Viral Genetics
About VRAL Viral Genetics, Inc., a biotechnology company, discovers and develops immune-based therapies for the treatment of HIV/AIDS and other infectious, autoimmune, and immunological deficiency disorders. It develops its products using its thymus nuclear protein compound. The company’s product includes VGV-X for the treatment of HIV infection and AIDS. It also develops VGV-L for Lyme read more
Viral Genetics’ P-IND Clears FDA To Commence Clinical Trials in Humans
Set to Begin First Ovarian Cancer Study Test Site for Metabolic Disruption Technology (MDT) Combination Therapy
A physician-initiated Investigational New Drug (P-IND) application submitted to the FDA in late April, 2012, has cleared the FDA’s screening process with the requirement for a regular IND application being read more
To see the headquarters in Google Street View &trade, drag this yellow guy: 
over to the red pointer: 
